SCHEMBL14728208

SCHEMBL14728208

CC(C)(C)[Si](C)(C)Oc1ccc(CC(Br)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.44
LAP3 P28838 1/20 0.44
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
ALDH1A1 P00352 1/20 0.40
BTN3A1 O00481 1/20 0.39
TSHR P16473 1/20 0.39
PPARG P37231 4/20 0.39
PPARA Q07869 4/20 0.39
MAOB P27338 1/20 0.39
PREP P48147 1/20 0.38
PPARD Q03181 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
ATM Q13315 1/20 0.38
CTSB P07858 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13535118 0.87 LTA4H (0.49) LTA4HLAP3ITGB3ITGA2BALDH1A1
SCHEMBL14728209 0.83 PREP (0.39) ITGB3ITGA2BPREPADRB3ATM
SCHEMBL14728212 0.83 LDHA (0.44) ITGB3ITGA2BPPARGPPARAPREP
SCHEMBL13535121 0.83 EPOR (0.44) LTA4HLAP3ITGB3ITGA2BBTN3A1
SCHEMBL13535725 0.81 ITGB3 (0.45) LTA4HLAP3ITGB3ITGA2B
SCHEMBL23501187 0.81 ALDH1A1 (0.60) ALDH1A1TSHRADRB2ADRB1ADRB3
SCHEMBL1701856 0.81 ITGB3 (0.67) ITGB3ITGA2BALDH1A1CTSB
SCHEMBL12052784 0.81 ITGB3 (0.67) ITGB3ITGA2BALDH1A1CTSB
SCHEMBL305427 0.79 TDP1 (0.50) ALDH1A1FFAR1FFAR4
SCHEMBL3907320 0.79 PRKCA (0.42) ALDH1A1BTN3A1PREPADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131121-A1 BRANCHED DISCRETE PEG CONSTRUCTS AUDAX PRIVATE DEBT LLC, AS AGENT 2023-04-27 US disclosed
US-20230131121-A1 BRANCHED DISCRETE PEG CONSTRUCTS AUDAX PRIVATE DEBT LLC, AS AGENT 2023-04-27 US disclosed
EP-2750681-B1 BRANCHED DISCRETE PEG CONSTRUCTS QUANTA BIODESIGN LTD (US) 2020-05-27 EP disclosed
US-20170313656-A1 Branched Discrete PEG Constructs QUANTA BIODESIGN, LTD. 2017-11-02 US disclosed
US-20150065711-A1 Discrete PEG Constructs EQUIP, LLC (US) 2015-03-05 US disclosed
US-20130052130-A1 Branched Discreet PEG Constructs UNIVERSITY OF WASHINGTON (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313656-A1 Branched Discrete PEG Constructs BTD, IDUA, DNPEP LTA4H 1024/4885LAP3 155/4885ITGB3 1193/4885
US-20150065711-A1 Discrete PEG Constructs MUC1, EGFR, LNPEP LTA4H 4033/4885LAP3 405/4885ITGB3 1886/4885
US-20230131121-A1 BRANCHED DISCRETE PEG CONSTRUCTS BTD, IDUA, DNPEP LTA4H 917/4885LAP3 154/4885ITGB3 1211/4885
US-20130052130-A1 Branched Discreet PEG Constructs BTD, DNPEP, IDUA LTA4H 1222/4885LAP3 151/4885ITGB3 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.